When the “Mu” attacks, Bioperfectus fights

Company news
2021-09-03

The Mu variant (known as B.1.621), first identified in Colombia in January 2021, has been added to the WHO’s VOI list on 30 August. Until now it was detected in 39 countries and found to possess a cluster of mutations that might make it less susceptible to the immune protection, according to the WHO’s weekly bulletin on the pandemic.

 

Although the global prevalence of the variant among sequenced cases are currently below 0.1%, its prevalence in Colombia and Ecuador has consistently increased, where it accounts for 39% and 13% of Covid cases respectively.

 

Some concern aboutMucomes from the particular mutations it carries, such as the P681H, E484K etc., which may help the virus evade immunity defenses and transmit faster.

 

https://covdb.stanford.edu/page/mutation-viewer/#sec_b-1-621

 

Under the investigation of Bioperfectus R&D team, we hereby conclude thatBioperfectus COVID-19 Coronavirus Real Time PCR Kit, COVID-19 Coronavirus (ORF1ab/N/E) Real Time PCR Kit and COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit are confirmed to stay effective and free from the impact of the variant B.1.621.

 

Fact Sheet: Bioperfectus Products Free from the Impact of the VOCs & VOIs Declared by WHO*Updated by 2021/09/03

 

 

References:

https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-august-2021

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14